Fasenra, AstraZeneca’s add-on maintenance treatment for patients with severe asthma, has received U.S. Food and Drug Administration approval.

Fasenra is approved for patients 12 and older with an eosinophilic phenotype, but not for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.

AstraZeneca CEO Pascal Soriot said this is the first approval for the company’s respiratory biologics portfolio. It will be available in the U.S. within weeks.